Volpara Health reports rise in revenue
It now has more than a quarter of the US market, the breast screening technology company says.
Breast cancer screening software company Volpara Health says it has ended its financial year in a strong position despite the Covid-19 pandemic.
The Wellington-based, ASX-listed firm has reported revenue of $18 million for the year to March, beating its target of $17.8m and up 172% on the
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly
credit card debit
Yearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
